What is known and objective: Obsessive-compulsive disorder (OCD) is a chronic neuropsychiatric disorder. Selective serotonin reuptake inhibitors (SSRIs) are the first line of medication for OCD treatment; however, 40%-60% of patients with OCD do not respond to SSRIs adequately. There are growing pieces of evidence which suggest a significant role for the glutamatergic system in the genesis of OCD and its consequent treatment. In the present study, we aimed to assess the association of SLC1A1 polymorphisms (rs301430, rs2228622 and rs3780413) with OCD and its clinical characteristics, as well as the importance of these SNPs in the response of OCD patients to SSRI pharmacotherapy.
| WHAT IS K NOWN AND OBJEC TIVE
Obsessive-Compulsive Disorder (OCD) is a chronic neuropsychiatric disorder which is the fourth most common mental disorder worldwide.
1 Patients with OCD are not able to control the continuous flow of disturbing and irrational thoughts (obsessions) that enter their mind, causing stress and leading them to behave in a particular repetitive manner (compulsions) to neutralize the undesired impulses (obsessions). These disturbing repetitive activities can negatively affect the person's daily life.
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Obsessive-compulsive disorder is a multifactorial disorder with high genetic pre-disposition. 1 Since monoaminergic systems in the brain, such as serotonergic, noradrenergic and dopaminergic systems, have been the centre of focus in the neurobiological studies of mood disorders including OCD, most of the therapeutic strategies target these systems. Selective serotonin reuptake inhibitors (SSRIs) are the first line of medication for OCD treatment.
3 Despite the effectiveness of these drugs in the treatment of OCD, about 40%-60%
of patients do not respond favourably to SSRIs.
1 Determining an effective SSRI for each OCD patient may not only increase prognosis but also economic and social costs incurred during treatment as well.
So, identifying the critical factors in determining success of OCD pharmacotherapy needs great attention and rigorous investigations.
There is increasing evidence suggesting a significant role for the glutamatergic system in the OCD aetiology and its consequent treatment. 4 Imaging and biological studies demonstrating sustained glutamatergic neurotransmission in key parts of the brain resulted in the glutamate hypothesis of OCD. 5 According to five independent family based-association studies, as well as a case-control study, the SLC1A1 gene is most consistently associated with OCD. [6] [7] [8] [9] [10] [11] Disruption of glutamatergic transmission in the cortico-striatal-thalamo-cortical (CSTC) circuitry plays a role in OCD pathogenesis. 12, 13 Higher glutamate concentrations in cerebrospinal fluid of patients with OCD compared to control groups have been reported. 14 Moreover, a decreased amount of glutamate in the anterior cingulate cortex of children with OCD has been observed. 4 Modified glutamate receptor levels have also been reported in brain areas within OCD subjects. 15 It has been reported that serotonin can influence dopaminergic activity indirectly through the glutamatergic and GABA-ergic systems.
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Glutamate transporter family is a group of transporter proteins which transfer glutamate across the cell membrane. The present study aimed to examine the association of three SLC1A1 polymorphisms (rs301430, rs2228622 and rs3780413) with OCD and its clinical characteristics as well as their importance in OCD patients' response to SSRI pharmacotherapy. severities were assessed using Y-BOCS severity scale before start of treatment course and after its completion at the end of 3 months pharmacotherapy. According to the differences between these two severity scores, patients were divided into three groups: responders, patients who showed >25% reduction in Y-BOCS severity score 
| MATERIAL S AND ME THODS

| Clinical samples
| Genotyping
Genomic DNA was isolated from peripheral leucocytes by salting out method. Primers were designed to study three SLC1A1 SNPs including rs301430, rs2228622 and rs3780413 (Table 1) 
| Statistical analysis
To assess Hardy-Weinberg equilibrium for all the studied poly- 
| RE SULTS AND D ISCUSS I ON
| Participant profile
As shown in Figure 1 , out of 282 patients who were included in the current study, 39 patients were excluded because of not giv- 
| Genetic association analyses
The associations of SLC1A1 SNPs with OCD were evaluated under the four genetic models (Co-dominant, dominant, recessive and over-dominant) (Table 3) and results showed that none of the SNPs were associated with OCD.
Results of the association analyses of SLC1A1 SNPs with the clinical variables, including the age of OCD onset and family history of psychiatric disorders, are summarized in Table 4 .
Patients were classified as early onset if their symptoms began 
TA B L E 4 (Continued)
at ≤18 years of age, otherwise they were deemed as late onset.
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Allele frequencies and genotypic distributions of SNPs did not show any difference between early-and late-onset patients, as well as patients with family history of psychiatric disorders, and patients reporting no family history, even by sex differences. The only significant difference detected was between the rs3780413 allele frequencies with the family history of psychiatric disorders in men (P = 0.000).
To assess the differences between obsession, compulsion and total severities of patients with different genotypes, mean severities were compared using a one-way ANOVA test, but no significant differences were detected (Figure 2 ).
| Pharmacogenetic association analyses
Interestingly, pharmacogenetic association analyses detected the associations of two SLC1A1 SNPs, rs2228622 (P = 0.031) and rs3780413 (P = 0.008), with OCD treatment response ( Table 5 ). As it was previously explained, non-responder and refractory patients were different groups of patients; the former group was just checked for the fluvoxamine treatment response but the latter consisted of patients who tried different SSRIs but didn't respond to them adequately. However, in the case of combining non-responder patients with the refractory patients, significant differences disappeared (data not shown).
| Main findings
Obsessive-compulsive disorder is a complex multifactorial disorder which seems to be influenced by the environment and genetic factors as well. Recent reports suggested a role for glutamate transporter genetic variations in OCD aetiology and treatment response.
Our results did not show any association between three studied glutamate transporter polymorphisms (rs301430, rs2228622 and rs3780413) and OCD, except an association between the familial form of the disease in men with rs2228622 (P = 0.033). The pharmacogenetic study also showed significant associations between rs2228622 and rs3780413 with fluvoxamine treatment response.
Several studies evaluated the association of OCD with different genes within serotonin, dopamine and glutamate pathways, as well as growth factors and those involved in white matter formation, but the results were inconsistent. 23 The only gene that has almost been consistently associated across OCD samples is the glutamate transporter gene, SLC1A1. 24 SLC1A1 has been considered as one of the most influential biological candidate genes for OCD, based on the results of linkage and association studies. 25 SLC1A1 was also reported to be associated with atypical antipsychotic-induced obsessive-compulsive symptoms 4 and with autism, a disorder frequently associated with obsessive-compulsive behaviours. 24, 26 Some findings showed that rs3780412 and rs301443 were associated with OCD, 10, 27 and its familial form. and their haplotype were reported to be significantly associated with OCD.
6 SLC1A1 rs3780412 and rs301430 were also found to be associated with early-onset OCD. 7 In another report, associations were detected in rs2228622 and rs3780412 under the dominant model in OCD. 4 Two haplotypes at three SNPs, rs3087879, rs301430 and rs7858819, were observed to be associated with OCD.
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Despite mentioned positive reports, there is a recent negative report in which no significant associations were detected between six SNPs (rs2228622, rs3780412, rs301430, rs301434, rs3087879
and rs301443) or haplotypes of SLC1A1 and OCD in a sample of Korean probands and controls.
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In present study, we have observed no associations between SLC1A1 polymorphisms (rs301430, rs2228622, and rs3780413) and OCD in an Iranian population except an association of familial form of the disease in males with rs2228622. This discrepancy may be related to the different ethnicity of patients compared to the previously studied population, suggesting the importance of population-specific genetic studies. However, interestingly enough, we detected a significant association between rs2228622 and rs3780413 polymorphisms and fluvoxamine pharmacotherapy response in Iranian OCD patients, when we included all of the pharmacogenetics groups.
There are limited studies investigating the role of glutamate pathway in response to SSRIs; however, preliminary support for the association of SLC1A1 with antidepressant response was provided. 
| Limitations
The most important limitations of this study are the sample size and the high rate of dropouts/lack of completion treatment, so further replication studies with larger samples is advised.
| WHAT IS NE W AND CON CLUS I ON
This is the first study that evaluates the role of glutamate transporter in OCD susceptibility considering family history, time of disease onset and sex differences in Iranian OCD patients.
Furthermore, the association of SLC1A1 genetic polymorphisms with fluvoxamine treatment response in OCD was provided for the first time.
In conclusion, detection of a comprehensive genetic overview of OCD as long as elucidation of effective genetic factors in its treatment may help with more accurate diagnosis, more effective therapeutic strategies and reduced economic and emotional cost to the individual, family and society at large.
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